Innovation

If you ask someone within the pharma world of statisticians on what is the hottest topic, you most likely will just get: Estimands!

Many scientific events, conference sessions, publications and presentations are organized around this topic. Thus, I’m super happy, that we have Mouna and Chrissie on the podcast as they have presented about this topic at various occasions.

In this episode, you will learn about

• the importance of the concept itself and it’s implications
• the terminology of the estimand framework
• and how it relates to missing data terminology

The episode covers the following questions and gives some examples on the different parts of the framework:

Do you think, you have nothing to add to a statistical conference? Are you afraid of sharing your achievements? Do you wonder, why you should put in the effort on top of your day-to-day job?

All these thoughts and questions will be addressed in this episode with Paul Terrill, the chair of the scientific committee of PSI. 

Beyond the questions above, we will also talk about the logistics and practical tips on how to submit your abstract and to become a speaker at next years conference.

Alex Dmitrienko has researched and published so much, that without a doubt, he can be called one of the world class experts in the field of multiplicity. E.g. his book Multiple Testing Problems in Pharmaceutical Statistics contains a wealth of practical information on this topic.

His career has brought him from pharma over CROs to his own company Mediana. Via his company, he provides also online courses on his favourite topic. Please access these here!

Indirect comparisons provide evidence, when no direct clinical trials are available. However, the different approaches come with various limitations. Some more recent approaches take into account the baseline characteristics to reduce the bias in the estimates of the treatment effects.

In todays episode, I’m talking with one the worlds experts on this topic – Nicky Welton – who has published extensively in this field. [Read more…] about Multilevel Network Meta-Regression for population-adjusted treatment comparisons – Interview with Nicky Welton